Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas

Recently, molecular therapies targeting epidermal growth factor receptor (EGFR) have been developed for clinical use. The current study was conducted to determine 1) the exact frequency of EGFR protein overexpression, 2) the correlation between protein overexpression and EGFR amplification, and 3) the correlation between the status of the genetic and clinicopathologic features in nonsmall cell lung carcinomas (NSCLC).

[1]  K. Zänker,et al.  Modulation of Epidermal Growth Factor Receptor Gene Transcription by a Polymorphic Dinucleotide Repeat in Intron 1* , 1999, The Journal of Biological Chemistry.

[2]  Y. Shimosato,et al.  Histological Typing of Lung and Pleural Tumours , 1999, World Health Organization.

[3]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[4]  A. Scott,et al.  A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[5]  F. Hirsch,et al.  Epidermal growth factor receptor family in lung cancer and premalignancy. , 2002, Seminars in oncology.

[6]  Xiaoling Li,et al.  Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study , 2004, Modern Pathology.

[7]  F. Waldman,et al.  Patterns of epidermal growth factor receptor amplification in malignant gliomas. , 1996, The American journal of pathology.

[8]  H. Fujii,et al.  Expression of epidermal growth factor receptor in gastric carcinomas. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  C. Liedtke,et al.  Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma , 2004, Laboratory Investigation.

[10]  H. Sugimura,et al.  Initial Intermittent Microwave Irradiation for Fluorescence In Situ Hybridization Analysis in Paraffin-Embedded Tissue Sections of Gastrointestinal Neoplasia , 2000, Laboratory Investigation.

[11]  S. Rodenhuis,et al.  Cellular protoonocogenes are infrequently amplified in untreated non-small cell lung cancer. , 1989, British Journal of Cancer.

[12]  Melissa A. Wilson,et al.  A strong intronic enhancer element of the EGFR gene is preferentially active in high EGFR expressing breast cancer cells , 2001, Journal of cellular biochemistry.

[13]  John J Spinelli,et al.  HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization , 2001, Modern Pathology.

[14]  C. Balch,et al.  AJCC Cancer Staging Manual. 6th ed , 2002 .

[15]  K. Asano,et al.  Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck. , 1989, British Journal of Cancer.

[16]  P. Harari,et al.  Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). , 2002, Cancer research.

[17]  Keith Wilson,et al.  Silence of chromosomal amplifications in colon cancer. , 2002, Cancer research.

[18]  R. Poulsom,et al.  The epidermal growth factor receptor in human pancreatic cancer , 1992, The Journal of pathology.

[19]  Y. Dobashi,et al.  Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: protein overexpression, gene amplification and activation of downstream molecules , 2004, Modern Pathology.

[20]  R. Evans,et al.  Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. , 1984, Science.

[21]  Chan Zeng,et al.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Hölscher,et al.  Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  M. Wrann,et al.  Identification of epidermal growth factor receptors in a hyperproducing human epidermoid carcinoma cell line. , 1979, The Journal of biological chemistry.

[24]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[25]  N. Reinmuth,et al.  Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. , 2000, The European respiratory journal.

[26]  Y. Oda,et al.  Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues. , 2002, Human pathology.

[27]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[28]  R. Figlin,et al.  Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer , 1999, Journal of Cancer Research and Clinical Oncology.

[29]  K. Kono,et al.  Status of c‐erbB‐2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme‐linked immuno‐sorbent assay , 2002, International journal of cancer.

[30]  M Paesmans,et al.  The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis , 2002, European Respiratory Journal.

[31]  H. Fujii,et al.  Detection of c‐erbB‐2 (HER‐2/neu) amplification in breast carcinoma by fluorescence in situ hybridization on tissue sections and imprinted cells , 2002, Pathology international.

[32]  G. Wahl,et al.  Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Fornace,et al.  Identification of an additional p53-responsive site in the human epidermal growth factor receptor gene promotor , 1997, Oncogene.

[34]  R. Pazdur,et al.  FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. , 2003, The oncologist.

[35]  竹花 卓夫.  Status of c-erbB-2 in gastric adenocarcinoma : A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay , 2003 .

[36]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  F. Waldman,et al.  EGF‐r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization , 1998, The Journal of pathology.

[38]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[39]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[40]  M. Noguchi,et al.  Amplification of protooncogenes in surgical specimens of human lung carcinomas. , 1989, Cancer research.